🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12121288

Combination tumor treatment

Regents of the University of Minnesota · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121523

Method of treatment of attention deficit/hyperactivity disorder (ADHD)

Supernus Pharmaceuticals, Inc. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12122998

Materials and methods for treatment of usher syndrome type 2A and/or non-syndromic autosom

CRISPR THERAPEUTICS AG · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12115136

Fortified CBD oil for treatment of PTSD

Bright Green Corporation · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116405

Arthritis treatment

XBIOTECH INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116574

Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, vari

Northwestern University · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12116589

Treatment of amyotrophic lateral sclerosis (ALS)

VOYAGER THERAPEUTICS, INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109272

Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and

Corcept Therapeutics Incorporated · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109229

Treatment of neurodegenerative disease with sodium chlorite

The Regents of the University of California · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109230

Treatment of neurodegenerative disease with sodium chlorite

The Regents of the University of California · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109225

Methods for potentiating cancer treatment using ionizing radiation

GLYCOMIRA THERAPEUTICS, INC. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109201

Methods and compositions for treatment of epileptic disorders

OVID THERAPEUTICS INC. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109231

Treatment of neurodegenerative disease with sodium chlorite

The Regents of the University of California · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109196

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12109228

Treatment of neurodegenerative disease with sodium chlorite

The Regents of the University of California · Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12102642

Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid r

Corcept Therapeutics Incorporated · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12102640

Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal

United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12104163

Adeno-associated virus vectors for treatment of Rett syndrome

Sarepta Therapeutics, Inc. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12102646

Compositions for the treatment of fibrosis and inflammation

Viking Therapeutics, Inc. · Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097213

Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation thera

The Board of Regents of the University of Texas System · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12098118

Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addicti

Regents of the University of Minnesota · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097188

Compositions and methods for the treatment of macular degeneration

Aldeyra Therapeutics, Inc. · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12097198

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12090140

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted